Back to Search
BRAD KAHL, MD
MD
Medical Oncology Physician
NPI: 1407822430IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
2015029481(MO)
Education
TUFTS UNIVERSITY SCHOOL OF MEDICINE
Class of 1994
Research & Publications (20)
The use of diethyl pyrocarbonate and potassium permanganate as probes for strand separation and structural distortions in DNA.
PMID 19378160·Methods Mol Biol·2009
8-other
The use of diethyl pyrocarbonate and potassium permanganate as probes for strand separation and structural distortions in DNA.
PMID 11357619·Methods Mol Biol·2001
7-preclinical
DNA melting and promoter clearance by eukaryotic RNA polymerase I.
PMID 10860723·J Mol Biol·2000
7-preclinical
Characterization of clinical Enterococcus faecalis small-colony variants.
PMID 19605585·J Clin Microbiol·2009
5-case
Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis.
PMID 19282318·Thorax·2009
4-observational
Emergence of respiratory Streptococcus agalactiae isolates in cystic fibrosis patients.
PMID 19247473·PLoS One·2009
8-other
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
PMID 19074748·Ann Oncol·2009
3-trial
Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies.
PMID 19544775·Med Phys·2009
3-trial
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
PMID 18668698·Hematol Oncol·2009
3-trial
Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma.
PMID 18650178·Clin Lymphoma Myeloma·2008
3-trial
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
PMID 18708367·Mol Cancer Res·2008
8-other
Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.
PMID 18203012·Leuk Lymphoma·2008
3-trial
Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia.
PMID 19052977·Leuk Lymphoma·2008
3-trial
Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients.
PMID 18613223·Hematol Oncol·2008
8-other
Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.
PMID 18381103·Semin Hematol·2008
6-review
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
PMID 18489772·Mol Cancer·2008
7-preclinical
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
PMID 18559976·Blood·2008
4-observational
The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates.
PMID 18378706·Antimicrob Agents Chemother·2008
8-other
Special problems in B-cell lymphoma: an historical perspective.
PMID 19074107·Hematology Am Soc Hematol Educ Program·2008
8-other
Marginal zone lymphomas: management of nodal, splenic, and MALT NHL.
PMID 19074110·Hematology Am Soc Hematol Educ Program·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4921 PARKVIEW PL, DIV IM MEDICAL ONCOLOGY, STE 7A, 7B, 7C
SAINT LOUIS, MO 63110 - Phone
- (800) 647-2098
Quick Facts
- NPI
- 1407822430
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile